NASDAQ:CSBR - Champions Oncology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Champions Oncology Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.50 -0.31 (-3.97 %) (As of 12/10/2019 10:43 AM ET) Add Compare Today's Range$7.23Now: $7.50▼$7.8550-Day Range$5.10MA: $5.82▼$7.9152-Week Range$4.98Now: $7.50▼$12.80Volume23,662 shsAverage Volume55,558 shsMarket Capitalization$87.12 millionP/E Ratio749.73Dividend YieldN/ABeta1.2 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CSBR Previous Symbol CUSIPN/A CIK771856 Webhttp://www.championsoncology.com/ Phone201-808-8400Debt Debt-to-Equity Ratio2.06 Current Ratio0.80 Quick Ratio0.80Price-To-Earnings Trailing P/E Ratio749.73 Forward P/E Ratio749.73 P/E GrowthN/A Sales & Book Value Annual Sales$27.07 million Price / Sales3.22 Cash Flow$0.06 per share Price / Cash Flow124.22 Book Value$0.19 per share Price / Book39.46Profitability EPS (Most Recent Fiscal Year)$0.01 Net Income$130,000.00 Net Margins-3.61% Return on Equity-48.07% Return on Assets-8.70%Miscellaneous Employees92 Outstanding Shares11,620,000Market Cap$87.12 million Next Earnings Date12/16/2019 (Estimated) OptionableNot Optionable Receive CSBR News and Ratings via Email Sign-up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CSBR Rates by TradingView Champions Oncology (NASDAQ:CSBR) Frequently Asked Questions What is Champions Oncology's stock symbol? Champions Oncology trades on the NASDAQ under the ticker symbol "CSBR." How were Champions Oncology's earnings last quarter? Champions Oncology Inc (NASDAQ:CSBR) issued its earnings results on Monday, September, 16th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.03 by $0.09. The biotechnology company earned $6.74 million during the quarter, compared to analysts' expectations of $7.50 million. Champions Oncology had a negative return on equity of 48.07% and a negative net margin of 3.61%. View Champions Oncology's Earnings History. When is Champions Oncology's next earnings date? Champions Oncology is scheduled to release their next quarterly earnings announcement on Monday, December 16th 2019. View Earnings Estimates for Champions Oncology. What price target have analysts set for CSBR? 4 brokerages have issued 1-year target prices for Champions Oncology's shares. Their forecasts range from $9.25 to $17.00. On average, they anticipate Champions Oncology's share price to reach $12.42 in the next twelve months. This suggests a possible upside of 63.4% from the stock's current price. View Analyst Price Targets for Champions Oncology. What is the consensus analysts' recommendation for Champions Oncology? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Champions Oncology. What are Wall Street analysts saying about Champions Oncology stock? Here are some recent quotes from research analysts about Champions Oncology stock: 1. According to Zacks Investment Research, "Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company's Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments. This technology can evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents. Champions Oncology, Inc. is based in Baltimore, Maryland. " (9/24/2019) 2. National Securities analysts commented, "Low risk way to invest in the development of oncology drugs: Champions Oncology (CSBR) sells products and services to pharmaceutical and biotechnology customers to help them quickly eliminate non-promising drugs, and determine the proper indications, dosage, and patient sub-populations for promising drug candidates. We believe that the company will continue to benefit from the expanding pipeline of oncology drugs. Sustained profitability: Champions reported two consecutive profitable quarters in F1Q19 and F2Q19. We believe that CSBR will continue to remain profitable in the second half of F2019 based on revenue growth of 34.1%, a rebound in gross margins to over 50%, and a solid control of operating expenses. In F2020, we project that revenues will grow by 22.7%, and operating margins will reach over 12.3% (compared to 5.3% in FY 2019) resulting in GAAP net income of $3.9 million ($0.27 EPS), up from $1.4 million ($0.10 EPS) in F2019. Expanding Cash Flow/Solid Balance Sheet: We believe that higher profitability will translate into cash flow from operations of $1.2 million in F2019 and $5.2 million in F2020. Concurrently, we expect cash will reach $2.3 million at the end of F2019 and $7.7 million at the end of F2020. Further, we anticipate CSBR will continue to remain debt-free and will not fund its growth plans through external financing Valuation: We believe that Champions is under-valued based on our price target of $17 a share. A discounted cash flow model would yield a value of $18.00 a share based on a discount rate of 10.8% and a terminal value of $12.5 a share, by our estimates. We assume that the company will start paying taxes in 2024, and will generate free cash flow of over $37 million in F2028. Based on an Enterprise Value to Sales multiple of 6x calendar 2020 revenues of $37.0 million, this would peg shares at a $16.00 valuation. Our $17 price target reflects an average of these two valuation methods. Our multiple reflects a slightly premium to small, fast growing life sciences companies that offer proprietary products and services for the oncology market. " (2/27/2019) Has Champions Oncology been receiving favorable news coverage? News stories about CSBR stock have been trending negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Champions Oncology earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Champions Oncology. Are investors shorting Champions Oncology? Champions Oncology saw a decline in short interest during the month of October. As of October 31st, there was short interest totalling 156,700 shares, a decline of 16.3% from the September 30th total of 187,200 shares. Based on an average trading volume of 32,900 shares, the short-interest ratio is currently 4.8 days. Approximately 2.7% of the company's shares are short sold. View Champions Oncology's Current Options Chain. Who are some of Champions Oncology's key competitors? Some companies that are related to Champions Oncology include PDL BioPharma (PDLI), Cellular Biomedicine Group (CBMG), Gritstone Oncology (GRTS), Eiger Biopharmaceuticals (EIGR), CASI Pharmaceuticals (CASI), Compugen (CGEN), Jounce Therapeutics (JNCE), ADMA Biologics (ADMA), Scholar Rock (SRRK), Sutro Biopharma (STRO), Cabaletta Bio (CABA), Solid Biosciences (SLDB), Aptose Biosciences (APTO), LogicBio Therapeutics (LOGC) and Nantkwest (NK). What other stocks do shareholders of Champions Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Champions Oncology investors own include Cytosorbents (CTSO), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), Crispr Therapeutics (CRSP), Corbus Pharmaceuticals (CRBP), Momo (MOMO), Sorrento Therapeutics (SRNE), Akers Biosciences (AKER), Cronos Group (CRON) and Mesoblast (MESO). Who are Champions Oncology's key executives? Champions Oncology's management team includes the folowing people: Dr. Ronnie Morris, CEO & Director (Age 53)Mr. David Barry Miller, Chief Financial Officer (Age 50)Dr. Philip P. Breitfeld, Chief Strategy & Innovation Officer and Director (Age 66)Mr. Mark Weinstein, Chief Information OfficerMr. Bruce Ruggeri, Chief Scientific Officer Who are Champions Oncology's major shareholders? Champions Oncology's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Cadence Capital Management LLC (2.14%), Tocqueville Asset Management L.P. (1.16%), Ingalls & Snyder LLC (1.14%) and Perkins Capital Management Inc. (0.56%). Company insiders that own Champions Oncology stock include Daniel Newman Mendelson, Joel Ackerman and Ronnie Morris. View Institutional Ownership Trends for Champions Oncology. Which institutional investors are selling Champions Oncology stock? CSBR stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Cadence Capital Management LLC and Ingalls & Snyder LLC. View Insider Buying and Selling for Champions Oncology. Which institutional investors are buying Champions Oncology stock? CSBR stock was bought by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P.. View Insider Buying and Selling for Champions Oncology. How do I buy shares of Champions Oncology? Shares of CSBR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Champions Oncology's stock price today? One share of CSBR stock can currently be purchased for approximately $7.60. How big of a company is Champions Oncology? Champions Oncology has a market capitalization of $88.31 million and generates $27.07 million in revenue each year. The biotechnology company earns $130,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. Champions Oncology employs 92 workers across the globe.View Additional Information About Champions Oncology. What is Champions Oncology's official website? The official website for Champions Oncology is http://www.championsoncology.com/. How can I contact Champions Oncology? Champions Oncology's mailing address is One University Plaza Suite 307, Hackensack NJ, 07601. The biotechnology company can be reached via phone at 201-808-8400 or via email at [email protected] MarketBeat Community Rating for Champions Oncology (NASDAQ CSBR)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 133 (Vote Outperform)Underperform Votes: 170 (Vote Underperform)Total Votes: 303MarketBeat's community ratings are surveys of what our community members think about Champions Oncology and other stocks. Vote "Outperform" if you believe CSBR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSBR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/10/2019 by MarketBeat.com StaffFeatured Article: What is the Fibonacci sequence?
